BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16801542)

  • 1. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
    Buchholz S; Keller G; Schally AV; Halmos G; Hohla F; Heinrich E; Koester F; Baker B; Engel JB
    Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10403-10407. PubMed ID: 16801542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.
    Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
    Endocr Relat Cancer; 2005 Dec; 12(4):999-1009. PubMed ID: 16322338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
    Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
    Chatzistamou I; Schally AV; Szepeshazi K; Groot K; Hebert F; Arencibia JM
    Cancer Lett; 2001 Sep; 171(1):37-45. PubMed ID: 11485826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A
    Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
    Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
    Cancer; 2005 Sep; 104(6):1312-21. PubMed ID: 16047355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
    Chatzistamou I; Schally AV; Sun B; Armatis P; Szepeshazi K
    Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
    Miyazaki M; Schally AV; Nagy A; Lamharzi N; Halmos G; Szepeshazi K; Armatis P
    Am J Obstet Gynecol; 1999 May; 180(5):1095-103. PubMed ID: 10329861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
    Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G
    Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy targeted to cancers through tumoral hormone receptors.
    Schally AV; Nagy A
    Trends Endocrinol Metab; 2004 Sep; 15(7):300-10. PubMed ID: 15350601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.
    Schally AV; Nagy A
    Eur J Endocrinol; 1999 Jul; 141(1):1-14. PubMed ID: 10407215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
    Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
    J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
    Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
    Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
    Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.
    Chen X; Zhang XY; Shen Y; Fan LL; Ren ML; Wu YP
    Oncotarget; 2016 Dec; 7(50):83451-83461. PubMed ID: 27825139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy.
    Nagy A; Schally AV
    Curr Pharm Des; 2005; 11(9):1167-80. PubMed ID: 15853664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin].
    Schally AV
    An R Acad Nac Med (Madr); 2004; 121(3):493-500. PubMed ID: 15751842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
    Keller G; Schally AV; Nagy A; Halmos G; Baker B; Engel JB
    Cancer; 2005 Nov; 104(10):2266-74. PubMed ID: 16211544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
    Miyazaki M; Nagy A; Schally AV; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P
    J Natl Cancer Inst; 1997 Dec; 89(23):1803-9. PubMed ID: 9392622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.
    Jungwirth A; Schally AV; Halmos G; Groot K; Szepeshazi K; Pinski J; Armatis P
    Cancer; 1998 Mar; 82(5):909-17. PubMed ID: 9486581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.